
News|Articles|November 1, 2024
AAV Production in Culture Biosciences’ 250mL Bioreactors
Author(s)Culture Biosciences
Adeno-associated virus (AAV) is a critical vector in gene therapy, but process robustness and scalability can pose challenges. This whitepaper demonstrates how Culture Biosciences' on-demand fleets of 250mL bioreactors enable large-scale experimentation and real-time data access to optimize upstream processes. Learn how process optimization can increase the fraction of full AAV capsids, accelerating your path to market.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
2
Advances in Continuous Manufacturing, Drug Delivery Lead CPHI Pharma Awards 2025
3
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
4
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
5
